Syensqo invests in Bioeutectics, a start-up producing green solvents

By Annabel Kartal-Allen | Published: 24-Jan-2024
Finance

The investment, made through Syensqo’s venture capital fund, will contribute to bring more sustainable products and processes to market

Syensqo Ventures, the group’s venture capital fund, participated in the $2.1 million financing round for Bioeutectics, alongside Fen Ventures, Atento Capital and SOSV (IndieBio).

This new investment strengthens the existing partnership between Syensqo Ventures and the Genesis Consortium, supporting startups in the SOSV’s IndieBio startup development program, the #1 early stage biotech incubator.


Syensqo, through its Renewable Materials and Biotechnology growth platform, is driven by a strong commitment to develop more sustainable solutions in the food, agro, industrial and biopharma sectors.


Based on pioneering technology - Natural Deep Eutectic Solvents (NADES), Bioeutetics mimics the way plants elaborate their own solvents, using 100% renewable sources. By replacing petrochemical-based solvents with natural alternatives, Bioeutectics provides solvents with an improved environmental, health, and safety profile that are aligned with and contribute to the achievement of sustainable development goals.

 

  • Companies:
  • Syensqo
See more

You may also like

Finance

Overcoming the dairy dilemma: Valio sees an increase in net sales

Read more
With many hurdles to overcome, Valio's net profits grew from 2022 by 2%

Trending Articles

  1. Overcoming the dairy dilemma: Valio sees an increase in net sales With many hurdles to overcome, Valio's net profits grew from 2022 by 2%
  2. Arla Foods Ingredients acquires Volac’s Whey Nutrition business The acquisition would allow Arla to utilise Volac's Felinfach site as a global production hub for its performance, health and food sectors
  3. Nutraceuticals: a major revenue opportunity for pharma companies There isn’t a single industry that hasn’t been affected by global economic disruptions in recent years. When searching for new revenue opportunities to mitigate these effects, many pharmaceutical companies are turning to nutraceuticals, reports Matevž Ambrožič, Marketing and PR Director at PharmaLinea
  4. Chinese consortium IVC to acquire Nutra Manufacturing from GNC International Vitamin Corporation will pay US$176 million for supplements production facilities in the US
  5. Kuehnle AgroSystems files patent for algae strain for astaxanthin Dr Adelheid Kuehnle, KAS founder and CEO, says the naturally sourced yellow strain is non-mutagenised and non-genetically engineered

Upcoming event

Vitafoods Europe

14–16 May 2024 | Exhibition | Palexpo, Geneva See all

You may also like

Finance

Overcoming the dairy dilemma: Valio sees an increase in net sales

With many hurdles to overcome, Valio's net profits grew from 2022 by 2%
Manufacturing

Arla Foods Ingredients acquires Volac’s Whey Nutrition business

The acquisition would allow Arla to utilise Volac's Felinfach site as a global production hub for its performance, health and food sectors
Finance

dsm-firmenich completes on-market repurchase of 500,000 shares to cover share plans

The company has repurchased 500,000 shares for a total consideration of €51.6m
Ingredients

Glanbia acquires Flavor Producers for $300m

The acquisition adds significantly to Glanbia's Better Nutrition platform, introducing novel flavour offerings
Ingredients

dsm-firmenich announces repurchase of 1.5m shares to cover share plans

The repurchasing of shares equates to around €156m
Ingredients

KAS announces $3M funding round to expand astaxanthin production

The company’s approach enables high-quality natural algae astaxanthin production at faster and more affordable rates
Finance

dsm-firmenich completes the divestiture of its Jiangshan vitamin C plant in China

Financial details of the transaction were not disclosed
Subscribe now